Selfie could say how long you'll live - as truth about Paul Rudd's age unveiled
A quick selfie could reveal to doctors how healthy someone is and how long they will live.
A new FaceAge AI tool can estimate a person's 'biological age' - as opposed to their actual age - by scanning an image of their face to predict the survival chances of cancer patients. Scientists say people age at different rates so their physical appearance may help give insights into how old a person is physiologically.
This biological age is based on many factors including lifestyle and genetics and can predict overall health and life expectancy. Researchers from Mass General Brigham network of hospitals in the US trained their algorithm using 59,000 photos.
Author Dr Hugo Aerts said: "Our study now has shown for the first time that we can really use AI to turn a selfie into a real biomarker source of ageing. The impact can be very large, because we now have a way to actually very easily monitor a patient's health status continuously and this could help us to better predict the risk of death or complications after, say, for example, a major surgery or other treatments.'
Scientists wanted to examine whether biological age could be examined based on how a person looks. This is similar to what doctors call the "eyeball test" - whereby certain judgments are made based on how a person looks, such as whether or not someone could undergo intensive cancer treatment based on how frail they appear to be.
But the research team said their 'deep learning' FaceAge tool went beyond this when used on 6,200 patients with cancer using images taken at the start of their treatment.
The academics found that the biological age of patients with cancer was, on average, five years older than chronological age. The findings, published in the journal Lancet Digital Health, showed that older FaceAge readings were associated with worse survival outcomes among patients with cancer, especially in people who had a FaceAge older than 85 years old.
The research team published an example referencing a popular online meme showing how the tool assessed the biological age of Hollywood actors Paul Rudd and Wilford Brimley based on photographs of the men when they were both 50 years old.
Rudd's biological age was calculated to be 42.6, while Brimley, who died in 2020, was assessed to have a biological age of 69. Paul Rudd, now aged 56, appeared in the TV series Friends and films including Anchorman, 40-Year-Old Virgin and Ant Man. Wilford Brimley appeared in films including The China Syndrome in 1979, The Thing in 1982, Tender Mercies in 1983, The Natural in 1984 and Cocoon in 1985.
Dr Ray Mak, co-senior author on the paper, said the selfie tool could be used by medics as "another piece of the puzzle like vital signs, lab results or medical imaging". He said: "We have demonstrated that AI can turn a simple face photo into an objective measure of biological age, that clinicians can use to personalised care for patients, like having another vital sign data point.
"We want to be clear that we view AI tools like FaceAge as assistance provide decision support and not replacements for clinician judgment."
More studies assessing FaceAge are under way, including whether it could be used for other conditions or diseases and what impact things like cosmetic surgery or Botox have on the tool.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Sun
5 hours ago
- The Sun
The way you hold your phone reveals a lot about your hidden personality traits – which one are you?
THE way you hold your smartphone could reveal surprising secrets about your personality – from how you work to the way you love. Experts say everything from using a single thumb to scrolling with both hands gives away clues about your confidence, decision-making and career strengths. 2 Phone in one hand If you casually hold your phone in one hand and scroll with the thumb, you radiate confidence without trying. You're upbeat, make others laugh, and have a knack for rallying people together. 'You might excel in fields like marketing, sales, or event organising that require a lot of energy and fast thinking.' Friends are drawn to you because you make them feel good about themselves. In work, you're the one who jumps in to lead a project. Your enthusiasm is infectious, though your love of risk means you sometimes leap before you look. The quirky findings come from lifestyle experts at TOI Lifestyle Desk, reported in They say your phone-holding style can uncover deep-rooted behaviours that influence your life choices. One thumb, both hands Holding your phone with both hands but scrolling with one thumb shows a methodical, cautious nature. You're the reliable friend or colleague who double-checks everything before acting. 'You're a good fit for professions that need accuracy, such as project management, engineering or finance.' Everyone can see the sea of logos but you've got the mind of a tech guru if you can find the odd one out in 10 seconds People trust you to get things right, whether it's planning a big event or balancing the books. You prefer structure over chaos and like knowing exactly what's coming next. That might make you seem a bit safe, but your steadiness is exactly what keeps things on track. Both thumbs, both hands Using both thumbs while gripping the phone firmly signals speed, precision and high energy. You thrive in fast-paced jobs and handle pressure well. 'You are always ahead of the curve, flexible and forceful,' making you ideal for roles in operations, journalism, aviation or tech. You're the person who takes charge when everyone else is flapping. Deadlines, emergencies and last-minute changes don't faze you. If anything, you thrive on them. Just remember to slow down now and then, or you could burn yourself out. Index finger scrolling Holding your phone in one hand and scrolling with your index finger suggests introspection and creativity. You think deeply before acting and see the world differently. 'Your ability to observe the world from a unique perspective is what sets your work apart.' You're the dreamer, the thinker, the one who spots details others miss. Whether it's art, writing, design or research, you excel in work that rewards originality. But your habit of overthinking can sometimes keep you stuck – learning to trust your gut could open even more doors. 2
Auto Express
6 hours ago
- Auto Express
It's incredible that no EV has got the full Electric Car Grant amount
As more cars become eligible for the Government's electric car grant, it's interesting that none of them yet qualifies for the higher £3,750 amount, with the total now sitting at 24 vehicles to choose from with a £1,500 contribution. With the latest batch of five including the likes of the Cupra Born, Volkswagen ID.3 and Peugeot 2008, there's now a decent array of cars included in the scheme, from the chic Renault 4 and 5 through to the practical, family-friendly Nissan Ariya – a former Auto Express Car of the Year! – the Vauxhall Frontera and the Renault Scenic. But it is interesting that nothing has yet achieved the full grant, especially as it's not clear from the outside how the calculations are being worked out. Advertisement - Article continues below Many industry commentators predicted the Renault 4 and 5 should be in pole position for the higher amount, but that didn't happen. That may have revealed something about where the batteries are coming from, and not all are yet being produced at the shiny new plant in northern France. When that facility is up to speed, there's a chance the Renault cars eligible for the grant – the 4, 5, Megane and Scenic are the ones that currently get £1,500 – could be moved to the higher level. But that's far from clear, due to the way the system has been set up. Skip advert Advertisement - Article continues below Want to make the switch to an electric car? Our fantastic Buy a Car service has loads of great value new and used electric cars available right now. I've heard some cynical types suggest glibly that the bar for eligibility for the full £3,750 has deliberately been set unachievably high, so the headlines featured a nice big number, but behind the scenes the Government knew full well that few cars, if any, were going to achieve it. I'm sure that wasn't the case, but the lack of clarity isn't helpful. From what I hear, even manufacturers don't know how close they have come to achieving the higher grant level – they can reapply if anything changes, such as battery supply coming from a different country. However, it sounds like there's little transparency as to why a car is only eligible at the lower level, and if it's down to the environmental credentials of where the batteries are built – coal reliance versus nuclear, for example. The big one will be when the UK-built Nissan Leaf goes on sale in the coming weeks; if that car isn't eligible, then I'm guessing nothing will be. At least the grant scheme will last longer if it's ebbing away at £1,500 a car, rather than nearly £4,000. Pessimistic early projections had it running out as soon as next spring if too many cars were eligible for the higher level. It's obvious that won't be happening now! Did you know you can sell your car with Auto Express? Get the highest bid from our network of over 5,500 dealers and we'll do the rest. Click here to try Auto Express Sell My Car now ... Find a car with the experts Forget Netflix, Volkswagen locks horsepower behind paid subscription Forget Netflix, Volkswagen locks horsepower behind paid subscription Owners can now subscribe to boost the power of their car… for a fee Shock new mid-size Range Rover to get EV power and stunning design Shock new mid-size Range Rover to get EV power and stunning design Mid-size SUV will end the four-year wait for a new JLR model and our exclusive images preview how it could look New Jaecoo E5 is a Range Rover lookalike with a very attractive price New Jaecoo E5 is a Range Rover lookalike with a very attractive price Chinese newcomer's first electric SUV is also a rival to the award-winning Kia EV3 and Hyundai Kona Electric
The Guardian
3 days ago
- The Guardian
Ozempic didn't work for me. I was furious
I'm 46 years old and I have been on a diet since I was 11. For as long as I can remember, eating has given me comfort. As a kid, I lied to my friends' parents so I could eat a second dinner at their house. I've never wanted just one cookie – I'd eat 12 and only stop when I felt physically ill, and sometimes not even then. In nearly every photo of me as a teenager I'm wincing, sucking in my stomach, trying to pose. I never really enjoyed the taste of these foods, nor was I happy with myself after eating them. They came with a side of guilt: you don't deserve this. This relentless food noise trapped me in a cycle of wanting to eat, then shaming myself for doing it. I spent inordinate energy hating my too tall, too big body. I always felt simultaneously like not enough and too much. Now, GLP-1 drugs like Ozempic, Wegovy and Mounjaro are being hyped as an easy fix to obesity. Their manufacturers have experienced significant revenue growth credited to the drugs' popularity; for instance, Eli Lilly recently announced 38% yearly growth, credited in part to sales of Zepbound and Mounjaro. Media headlines tout the changes in weight and appetite for those who take them. But what if the 'miracle' doesn't work for you? Being diagnosed with diabetes at age 27 threw me deeper into a shame spiral. At the time, my doctor clinically defined me as obese. That, along with the prognosis of a deficient pancreas, felt like punishment for decades of failing to control my overeating. Given my family history of diabetes – my grandpa had it – the doctor diagnosed me as type 2 and recommended dramatic lifestyle adjustments, including carb counting and daily exercise. She also did an A1C test, which measures average blood sugar levels for three months. A non-diabetic's result would be under 5.7%. Mine was 7.7%. This diagnosis felt like being sentenced to lifelong obsession. Food already controlled me, and now it had even more power. Over the next five years, I worked with a nutritionist and psychotherapist. I trained for a 200-mile relay race with friends. I did Weight Watchers, went to Overeaters Anonymous, worked the 12-step program, and used apps like Noom and My Fitness Pal. I lost 50lb. Still, I remained overweight according to the BMI chart, and my A1C didn't budge, which confounded my primary care doctor. She referred me to an endocrinologist who specialized in metabolic health. Six months later, when my appointment finally arrived, my A1C had shot up to 9.1%. That should not have happened while I shed pounds. She declared I was misdiagnosed: type 2 diabetics' bodies make insulin, which helps regulate blood sugar, but don't use it effectively. But I was actually type 1, an autoimmune condition where the body stops producing insulin. I would be dependent on insulin injections from that point forward. Living with diabetes was taxing. I had to order a continuous glucose monitor (CGM), pen needles, insulin vials and other items – but via a specialty supplier rather than a standard pharmacy, for insurance purposes. I had to procure pre-authorization forms for medication and attend required half-day training sessions every time I wanted to try a different insulin pump or when my insurance changed. In 2018, after five years of effort, my A1C settled in at 5.9% – a happy result for me and my doctor. But to get to a weight my doctor would approve, I still had to lose 30lb. She started me on a new drug called Ozempic. Like most people at that point, I'd never heard of it. She said it was only technically approved for type 2 patients – but some who were overweight with type 1, like me, were taking it to help with weight loss. Over the next four years, my doctor and I gradually increased my Ozempic dosage and eventually were pleased with the results: when I woke in the morning my fasting blood sugar reading was finally within the recommended range of 80-120 on my CGM. I was able to reduce my regular insulin usage. But my weight didn't change. I continued my healthier eating habits and exercised regularly with cycling, yoga and running. Still, the scale didn't move. In 2022, when Ozempic was becoming a household name, I suddenly had two problems. First, my doctor confirmed I was already on the highest available dose, so taking more wouldn't help me lose weight. Second, because the drugs were now approved for general weight loss, I might have trouble filling my prescription. A global shortage followed, and I went four months without, eventually switching to Mounjaro because it was available. My already-thin friends started taking GLP-1s, and I couldn't avoid chatter about the 'skinny shot'. 'I'm not even hungry! I don't even think about food!' they'd say. But I didn't experience this quieting of the voices in my head telling me I was hungry all the time, and I wondered why. I was furious. As my friends celebrated their new bodies, I wondered, again, what was wrong with mine. My diabetes was under control, but I was also existing at the margins of a miracle. An estimated 15% of all GLP-1 users are so-called 'non-responders' to the weight loss effect, according to Atlanta-based physician Dr Cristina Del Toro Badessa. Lucas Veritas, a GLP-1 user from Montreal and author of The GLP-1 Effect newsletter, highlighted clinical trials showing that approximately 13% of people taking semaglutide (the active ingredient in Ozempic and Wegovy) and about 9% of those taking tirzepatide (found in Mounjaro and Zepbound) did not lose more than 5% of their body weight. 'The meds are highly effective for a majority of patients but there is still a percentage who don't lose a clinically significant percentage of body weight. Everyone's physiology is a little different,' said Veronica Johnson MD, an obesity medicine specialist in Chicago. Recent research has identified a gene that may help predict who will successfully lose weight with GLP-1 medications. Sign up to Well Actually Practical advice, expert insights and answers to your questions about how to live a good life after newsletter promotion Additionally, according to a recent study comparing GLP-1 medications to bariatric surgery, 'real world' cohorts lost less weight than what drug companies reported in their trials: about 5% of their body weight, compared with the 15% reported for semaglutide and the 20–25% for tirzepatide in pharma-funded studies. Nicoletta LaMarca-Sacco, 56, a former Ozempic user in New York, also didn't lose weight after a year of use. 'I've always been a squishy mom and will continue to be,' she said. 'It just didn't work for me.' She expected the drug would quiet more of the internal chatter telling her she needed to snack. 'It did help, but only to a small degree,' she said. 'When we consider these drugs, they need to be combined with other markers of good health like diet, exercise, even stress management,' said Dr Raj Dasgupta, an ABIM Quadruple board-certified physician in Los Angeles. He said his patients sometimes had unrealistic expectations about how quickly and dramatically they will drop extra pounds. He explained that for someone who is overweight, shedding even a small amount of weight can improve heart and kidney function, adding: 'The bar has been set too high for weight loss.' 'What's dangerous,' Badessa said, 'is the dominant societal narrative that these are 'magic shots' for weight loss.' Veritas agreed: 'Expectations are sky-high. People see all the before/after photos and expect an easy ride.' 'It feels similar to any other time the diet industry has thrown marketing momentum behind one particular 'fix',' Virginia Sole-Smith, author of Fat Talk, told me about the current hype. 'There's excitement that we've found a 'silver bullet', then it silences any other narratives and experiences about it.' I had definitely been looking for an elixir to rid me of body mass. Then I discovered that diabetes itself might be the reason I wasn't losing weight. Andrew Koutnik, a metabolic research scientist, said that GLP-1s typically lead to significant weight loss for people with obesity (15-25% of their body weight). However, people with diabetes generally lost less weight, proportionally: for type 2, an average of 8-11%; for type 1, about 8-12%. 'While we don't know why this is occurring, prior data suggests the drug's metabolic effects may be tied to how well the body manages glucose,' Koutnik said. GLP-1s are designed to coax the body into making and using insulin more efficiently, he explained. But for someone with type 1 diabetes, meaning their pancreas cannot make insulin, that's like installing a turbocharger on a car with no engine – there's nothing to boost. That said, he clarified, these drugs aren't entirely useless for people with type 1. GLP-1s slow digestion and suppress appetite, which can lead to fewer snacks and less carb-heavy meals. That might nudge blood sugar in the right direction, but it's more of a side-effect. 'The actual impact on blood sugar control is minimal: less than a 1% drop in A1C,' Koutnik explained. The psychological fallout of being a non-responder can be devastating. It was more fodder for my destructive inner dialogue: Why won't my body just comply? Alyson Curtis, a therapist based in New York, works with patients who feel isolated as they see others losing weight and don't have the same result. I told her how unfair it felt and she agreed the loss of agency can be a lot to process. 'I hear the 'thin fantasy' constantly from patients – it's a dream to fit into societal norms,' Curtis added, 'but what they're really saying is they want to be accepted, cherished, adored.' She helps patients reframe success to focus on healthy outcomes beyond weight loss – like how the Health at Every Size (HAES) movement centers on overall wellbeing. Still, these drugs are here to stay. Johnson pointed to recent innovations like CagriSema, a compound drug bringing together an amylin agonist and a GLP-1. In trials, CagriSema helped reduce blood sugar spikes after meals and can also contribute to weight loss. 'The hormone called amylin is normally released by the same cells that make insulin – which type 1 diabetics lack,' Koutnik said. He added that amylin helps slow digestion and also lowers levels of glucagon, which could help better manage blood sugar. Society seems to have rewritten ideas about health, worth and willpower through the lens of these astonishing drugs. I figured I could, too. I've tried to quiet the inner voice that's shaming me into thinking I'm a failure for not losing more weight. Forging self-acceptance from deep frustration, I am realizing there is nothing inherently 'wrong' with my body – I am simply among those for whom the current medications produce a partial benefit. Learning that I'm not alone has helped curb my body shame. I am grateful that GLP-1s have helped me with blood sugar control, minimizing my risk of complications from diabetes. 'When we focus on the miracle weight loss narrative, we ignore their real value in helping people with diabetes, adding to the discourse of body shaming, which is never health-promoting,' said Sole-Smith. I've been trying to shift my focus from weight loss to improving my relationship with food. For me, that's learning to eat with more intention and maybe even a little joy. Hopefully, I can come to appreciate my right to the occasional indulgence without self-recrimination. And on my next birthday, I want to celebrate with the most delicious symbol of self-acceptance: a guilt-free piece of cake.
